Seed Therapeutics is focused on developing Molecular Glues that target previously undruggable proteins, utilizing the Ubiquitin Proteasome System to facilitate targeted protein degradation. This approach aims to create effective therapies for debilitating diseases such as cancer, neurodegeneration, and infectious diseases.
Funding
$44M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many disease-causing proteins are considered "undruggable" because traditional drug discovery methods cannot effectively target them. This limitation hinders the development of therapies for various diseases, including cancers, neurodegenerative disorders, and infectious diseases.
Solution
Seed Therapeutics is developing a platform of Molecular Glues that harness the ubiquitin proteasome system (UPS) to selectively degrade previously undruggable proteins. These small molecules induce proximity between E3 ubiquitin ligases and target proteins, leading to ubiquitination and subsequent degradation of the target protein by the proteasome. This targeted protein degradation (TPD) approach offers a novel therapeutic strategy for diseases where specific protein removal can provide clinical benefit. Seed Therapeutics is advancing a pipeline of drug candidates for oncology, neurodegeneration, and infectious diseases, collaborating with experts in the UPS field to overcome scientific barriers in molecular glue discovery.
Target Audience
The primary target audience includes patients suffering from cancers, neurodegenerative disorders, and infectious diseases, as well as pharmaceutical companies seeking novel therapeutic approaches.
Features
- Focus on discovering and engineering Molecular Glues for targeted protein degradation.
- Utilizes the Ubiquitin Proteasome System (UPS) to degrade disease-causing proteins.
- Development of small molecule drugs that induce proximity between E3 ubiquitin ligases and target proteins.
- Pipeline of drug candidates for oncology, neurodegeneration, and infectious diseases.
- Collaborations with leading academic experts in the Ubiquitin Proteasome System and Targeted Protein Degradation.
- IND candidate disclosed for cancer treatment.